Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWBU | ISIN: US21077P1084 | Ticker-Symbol: 6K9
Frankfurt
14.11.24
08:09 Uhr
1,830 Euro
-0,030
-1,61 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CONTEXT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CONTEXT THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7701,82020:18
1,7701,82020:11

Aktuelle News zur CONTEXT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.11.Context Therapeutics Inc.: Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results26Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board...
► Artikel lesen
CONTEXT THERAPEUTICS Aktie jetzt für 0€ handeln
16.10.Context Therapeutics Inc.: Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting6
27.09.Piper Sandler maintains price target on Context Therapeutics2
23.09.BioAtla out-licenses BA3362 to Context Therapeutics1
23.09.BioAtla Grants Exclusive, Worldwide License To Context Therapeutics To Develop BA33626
23.09.BioAtla licenses cancer drug candidate to Context Therapeutics1
23.09.BioAtla lizenziert Krebsmedikament-Kandidaten an Context Therapeutics4
23.09.BioAtla, Inc.: BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody133Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and...
► Artikel lesen
23.09.Context Therapeutics Inc.: BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody4
17.09.Context Therapeutics doubles authorized shares2
17.09.Context Therapeutics Inc. - 8-K, Current Report2
16.09.Piper Sandler maintains Overweight rating on Context Therapeutics stock1
16.09.Piper Sandler behält Übergewichtung für Context Therapeutics-Aktie bei1
09.09.Piper Sandler maintains Overweight rating on Context Therapeutics shares1
04.09.Context Therapeutics enhances board with new appointments1
04.09.Context Therapeutics Inc.: Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors1
04.09.Context Therapeutics Inc. - 8-K, Current Report1
08.08.Context Therapeutics GAAP EPS of -$0.042
08.08.Wainwright raises Context Therapeutics stock target on trial update2
07.08.Context Therapeutics Inc.: Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results135Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA...
► Artikel lesen
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1